MannKind reported $6.19M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Adma Biologics USD 1.83M 1.05M Jun/2025
Dynavax Technologies USD 1.64M 51K Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Halozyme Therapeutics USD 4.39M 131K Jun/2025
Insmed USD 21.24M 1.5M Jun/2025
MacroGenics USD 802K 826K Jun/2025
MannKind USD 6.19M 4.44M Jun/2025
Merck USD 305M 8M Jun/2025
Pfizer USD 654M 0 Jun/2025
Sanofi 148M 65M Jun/2025
Xencor 8.24M 422K Jun/2025